Investor Moves
| Name | Value | Action | Change | Price | Current Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-82.7K ExitQ1 2026 $83k -- $5.20 | |||||
News
businesswire.comTurn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitisbusinesswire.comJun 1
businesswire.comTurn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Modelbusinesswire.comMay 27
businesswire.comTurn Therapeutics to Present at Jefferies Global Healthcare Conference 2026businesswire.comMay 19
gurufocus.comTurn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Leadgurufocus.comMay 18
businesswire.comTurn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Leadbusinesswire.comMay 18